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The first edition of the Belgian guidelines on
antithrombotics and central neuraxial anesthesia
was published in the year 2000, followed by the
second edition in 2005 (1, 2). These guidelines pro-
vided Belgian anesthetists with a framework to hold
on to when managing patients treated with
antithrombotic therapy. Since 2005, however, new
information on the risk of central neural blocks in
patients treated with antithrombotics has emerged
and new antithrombotic agents have become avail-
able. In our modern Western civilization, cardiovas-
cular disease remains the number one cause of mor-
bidity and mortality and – as our population ages
progressively – there is an increased need for drugs
that prevent or treat arterial and/or venous throm-
boembolism. In addition, case reports suggesting
that the risk of a spinal hematoma may be higher
than previously thought (3-7) continue to appear in
the anesthetic literature. Taken together, these facts
all substantiate the necessity of an update of these
guidelines.
GUIDELINES
There are virtually no prospective data on the
use of central neuraxial anesthetic techniques in the
presence of antithrombotic drugs. The majority of
the available recommendations and guidelines on
the subject are expert opinions based on large case
series, case reports and the pharmacological data of
the individual antithrombotic drug involved. The
resulting recommendations will always include :
(1) a minimum time interval that should be observed
between the last dose of an antithrombotic drug and
the insertion of a neuraxial needle/catheter or the
manipulation/removal of that catheter, (2) a mini-
mum time interval that should be observed between
the insertion of a neuraxial needle/catheter or the
manipulation/removal of that catheter and the next
dose of antithrombotic, and in some cases, (3) the
need to perform a coagulation test prior to the
 performance of a neuraxial anesthetic technique.
For most of the antithrombotics included in
the present guidelines, there is a large body of
knowledge and experience available as they have
been available for some time. However, when new
drugs are discussed, it becomes more complicated.
New antithrombotic agents may differ in the onset
of action, the half-life and the antithrombotic poten-
cy. Unfortunately, more potent antithrombotic effi-
cacy goes hand in hand with increased bleeding
risk, whereas antagonizing agents are currently not
available for the new antithrombotics. Because of
the lack of experience with these new drugs, it is
mainly the pharmacological profile that must guide
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the clinician when using central neuraxial anesthe-
sia in patients treated with these new drugs.
ROSENCHER et al. proposed a strategy that can be
applied when new antithrombotic agents are used
for prophylaxis of venous thromboembolism (8). In
the presence of these drugs, central neuraxial inser-
tion of a needle and/or catheter and the subsequent
manipulation/withdrawal of the catheter should
only be performed at least 2 elimination half-lives
after the last dose of an antithrombotic has been
administered. Subsequently, the first or next dose of
that antithrombotic should only be administered
after a time interval obtained by subtracting the
time necessary for that specific antithrombotic to
reach therapeutic plasma levels after administra-
tion, from the time necessary to produce a stable
blood clot (i.e. 8 h).
The grading of the recommendations and the
level of evidence of the present guidelines has been
obtained by using the definitions of the Committee
for Practice Guidelines of the European Society of
Cardiology (ESC) (Table 1) (9). Also, these guide-
lines are not intended to bypass the clinical judg-
ment of the anesthetist. However, when the anes-
thetist decides not to comply with these guidelines,
we recommend to document the rationale in the
patient’s chart and informed consent from the
patient should be obtained.
Preferably, the perioperative cessation of
antithrombotic drugs so as to safely perform a
regional block should be discussed with the physi-
cian who initiated this therapy and the surgeon. An
alternative anesthetic technique should be used if it
is judged that the administration of the antithrom-
botic must not be interrupted, e.g. in patients with
recent coronary stenting.
The time windows mentioned in the present
guidelines are only valid in patients with a normal
pharmacological profile (Table 2). This includes a
normal body weight, and normal hepatic and renal
function.
The simultaneous administration of different
antithrombotic drugs is not considered. Such com-
binations may increase the risk of perioperative
hemorrhagic complications and necessitate greater
caution.
The antithrombotic agents that will be dis-
cussed in detail hereafter are : low molecular
weight heparins (LMWHs), unfractionated heparin
(UH), selective factor Xa inhibitors, direct throm-
bin inhibitors, vitamin K antagonists (VKAs), non-
steroidal anti-inflammatory drugs (NSAIDs),
antiplatelet agents and fibrinolytic/thrombolytic
agents. A list of these drugs with both their generic
and registered trade names is included in the text
(Table 3). Danaparoid, argatroban and cilostazol are
not (routinely) available in Belgium and are thus
not addressed in this text. If necessary, recommen-
dations concerning these drugs and neuraxial anes-
thesia can be found in the recently published
European Society of Anaesthesiology (ESA) recom -
mendations (10). Finally, a small section addressing
the issue of herbal medicines is included at the end.
RISK OF SPINAL HEMATOMA
Spinal hematomas are rare and mainly occur
spontaneously (11). In most cases, no direct cause
or contributing factor can be identified. Still, the
second and third most commonly identified causes
are concurrent antithrombotic therapy and the
Table 1
Classes of recommendation and levels of evidence
Classes of recommendations
Class I Evidence and/or general agreement that a given treatment or procedure is beneficial
Class II Conflicting evidence and/or divergence of opinion about the usefulness/efficacy of the treatment or
procedure
Class IIa Weight of evidence/opinion in favour of usefulness/efficacy
Class IIb Usefulness/efficacy is less well established by evidence/opinion
Class III Evidence or general agreement that the treatment or procedure is not useful or effective and in some
cases may be harmful
Level of evidence
Level A Data derived from multiple randomised clinical trials or meta-analyses
Level B Data derived from a single randomised clinical trial or large non-randomised studies
Level C Consensus of opinion of the experts and/or small studies, retrospective studies, registries
© Acta Anæsthesiologica Belgica, 2011, 62, n° 4
 presence of vascular malformations. In contrast, for
spinal bleeding associated with neuraxial anesthe-
sia, the use of antithrombotic therapy is the most
important risk factor (12, 13). Because of the rarity
of this dramatic event, it is virtually impossible to
get an accurate estimate of its incidence through
prospective studies. Estimates are often based on
the analysis of case reports. In 1993, Tryba estimat-
ed the incidence of a spinal hematoma to be 1 in
150 000 and 1 in 220 000 patients after epidural or
spinal anesthesia, respectively (14). More recent
data suggest that the actual incidence might be
higher, in particular in association with the use of
antithrombotic agents. Incidences ranging from 1 in
1000 to 1 in 10 000 neuraxial blockades were
reported in orthopedic patients treated with enoxa-
parin (15). The presence of an impaired coagulation
increased the bleeding incidence to 1 in 40 800, 1 in
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Table 2
Summary of recommended minimum time intervals or clotting times before and after central neuraxial needle puncture/catheter
insertion, manipulation or removal of catheters*





LMWH (prophylactic dose)# 12 h 4 h Platelet count if LMWH > 5 d
LMWH (intermediate or thera-
peutic dose)£
24 h 4 h Platelet count if LMWH > 5 d
UH
(therapeutic dose)
aPTT and/or ACT within nor-
mal range
1 h aPTT, ACTPlatelet count if UH
> 5 d
Fondaparinux 36-42 h 6-12 h Anti-Xa activity – assay stan-
dardized for specific agent§
Rivaroxaban
(≤ 10 mg/d)
22-26 h 6 h Anti-Xa activity – assay stan-
dardized for specific agent§
Rivaroxaban (>10 mg/d) 3 d 6 h Anti-Xa activity – assay stan-
dardized for specific agent§
Apixaban
(≤ 2.5 mg bid)
26-30 h 6 h Anti-Xa activity – assay stan-
dardized for specific agent§
Apixaban
(> 2.5 mg bid)
3 d 6 h Anti-Xa activity – assay stan-
dardized for specific agent§





6 h TT, ECT
Dabigatran
(> 220 mg/d)
4 d 6 h TT, ECT
Vitamin K
antagonists
INR ≤ 1.4 After catheter removal INR
NSAIDs None None
Dipyridamole None None
Acetylsalicylic acid None None
Ticlopidin 10 d After catheter removal
Clopidogrel 7 d After catheter removal
Prasugrel 10 d 6 h
Ticagrelor 7 d 6 h
Eptifibatide / tirofiban 8-10 h 2-4 h Platelet count
Abciximab 48 h 2-4 h Platelet count
ACT, Activated clotting time ; aPTT, activated partial thromboplastin time ; ECT, ecarin clotting time ; INR, international nor-
malised ratio ; NSAIDs, non-steroidal anti-inflammatory drugs ; TT, thrombin time. *All time intervals apply to patients with normal
body weight and normal hepatic/renal function. #Maximum prophylactic dosages of low molecular weight heparins are listed in
Table 4. £ Intermediate and therapeutic doses of LMWH are listed in Table 4. § Under development.
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Table 3
Generic and registered trade names of antithrombotic agents currently available in Belgium
Generic name Registered trade name









Unfractionated heparin Heparin Heparine Leo®
Heparine Natrium B. Braun®





























Dipyridamol Dipyridamol Dipryridamole EG®
Persantine®































* Not registered in Belgium yet.
© Acta Anæsthesiologica Belgica, 2011, 62, n° 4
6600 and 1 in 3100 patients following spinal
 anesthesia, single-shot epidural anesthesia and
epidural catheter techniques, respectively (7). Even
more worrisome were the findings of a Scandinavian
survey that was published in 2004 (6). The authors
reported a spinal hematoma in 1 in 3600 female
patients undergoing knee arthroplasty under epidur-
al anesthesia. More recent case series confirm these
higher incidences (3, 4, 16), although somewhat
more reassuring figures were published by COOK et
al., who found and incidence of vertebral canal
hematoma ranging from 1 in 88 000 to 1 in 140 000
central neuraxial blocks (5). This study furthermore
reported that the pediatric and obstetric populations
have the lowest risk in terms of spinal bleeding,
which thereby confirms previous reports that the
incidence of spinal hematoma after neuraxial
blocks is lowest in the obstetric population with
incidences ranging from 1 in 168 000 to 1 in
200 000 women (6, 17).
GENERAL RECOMMENDATIONS
Contributing factors
Routine laboratory investigations do not
always detect a hemorrhagic diathesis. A thorough
patient history and clinical examination are manda-
tory to detect an increased bleeding tendency.
Several conditions may be associated with altered
coagulation, such as the perioperative use of vari-
ous antithrombotic drugs, a low platelet count, renal
and/or hepatic failure, chronic alcoholism, chronic
steroid therapy, and the perioperative infusion of
dextrans. Unfractionated heparin and LMWHs
alone or in association with acetylsalicylic acid
(ASA), NSAIDs and/or thienopyridines are the
drugs most commonly involved (18). Other risk
factors include bloody, traumatic and/or multiple
punctures, the use of large bore needles, anatomic
abnormalities of the spinal cord, vascular malfor-
mations in the vicinity of the spinal cord (12, 19),
osteoporosis with spinal stenosis (6), Bechterew’s
disease (20), preexisting spinal canal patholo-
gy (21), the lack of guidelines on the use of central
neuraxial techniques in the presence of antithrom-
botics (6), female sex (6, 16, 22) and advanced
age (5, 6, 16). Advanced age is associated with
degenerative spine disorders and renal insufficien-
cy. As the elimination of many antithrombotic drugs
is kidney dependent, renal insufficiency may pro-
long and intensify the anticoagulant effects, thereby
increasing the bleeding risk if no dose adjustment is
performed. Finally, the use of epidural catheters,
and particularly their removal, is associated with
the highest bleeding risk, as almost two thirds of the
hematomas were described only after withdrawal of
the catheters (5, 6, 12, 18). If neuraxial blockade is
considered beneficial to a given patient, a spinal
anesthetic technique may be a valuable alternative
since current data from the literature suggest that
spinal puncture may be associated with a lower risk
of spinal hematoma when compared to epidural or
combined spinal-epidural anesthetic techniques (5,
7) (Class IIa, level C).
Spinal hematoma
All patients should be carefully observed for
signs of a developing spinal hematoma after neu-
raxial blockade or after removal of the neuraxial
catheter. A slow or absent regression of motor
and/or sensory block, back pain, urinary retention,
and the return of a sensory and motor deficit after a
previous (complete) regression of the block, alone
or in combination, suggest a developing spinal
hematoma (Class I, level B). Patients, nurses and
physicians should be taught the signs of a spinal
hematoma and should be instructed to contact an
anesthetist immediately (Class IIa, level C).
Postoperative analgesia with low concentrations
and/or low doses of local anesthetics and the inser-
tion of the epidural catheter at the thoracic level
will produce a minimal or absent motor block of the
lower limbs and thus facilitate the early detection of
a developing hematoma. In case of any doubt, the
epidural infusion of local anesthetics should be
stopped immediately in order to detect any neuro-
logical deficit as soon as possible.
When a clinical suspicion of spinal hematoma
formation arises, an aggressive diagnostic and ther-
apeutic approach is mandatory (Class I, level C).
This includes urgent magnetic resonance imaging
(MRI) or a CT scan. If the diagnosis is confirmed,
a decompressive laminectomy should be performed
less than 8 to 12 h after the appearance of the first
symptoms of medullary compression in order to
keep the patient’s chances of making a complete
neurological recovery intact (Class I, level B) (12,
23).
It is advisable that written protocols for the
management of suspected spinal hematoma, cover-
ing the assessment of motor and sensory function,
the diagnostic work-up with MRI or CT scanning,
and the referral to neurosurgery, are available in
every institution (10, 24) (Class IIb, level C).
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Thromboprophylaxis
Currently, LMWHs represent the mainstay of
perioperative thromboprophylaxis. There are only
small differences in efficacy between a pre- or post-
operative start. Both options are acceptable (25-27),
and in line with the most recent guidelines from
the American College of Chest Physicians
(ACCP) (28). However, as antithrombotic drugs
increase the risk of spinal bleeding after neuraxial
anesthetic techniques, we recommend to start pro-
phylactic LMWHs only postoperatively, especially
in patients also treated with ASA (Class IIb, level
B).
Regional anesthesia itself has some protective
effects against the occurrence of thromboembolic
complications. Improved pain relief allows an earli-
er mobilisation of the patients. Although the inhibi-
tion of a surgical stress reaction and local anesthet-
ics alter coagulation and fibrinolysis (29, 30),
regional anesthesia by itself does not increase
bleeding tendency (31) or has a thromboprophylac-
tic activity equivalent to or exceeding that of cur-
rent thromboprophylactic compounds (32).
LOW MOLECULAR WEIGHT HEPARINS
Prophylactic administration
Low molecular weight heparins are fragments
of UH that cause an antithrombin dependent inhibi-
tion of factors IIa and Xa. Bioavailability is almost
100% and the half-life is approximately of 4 to 7 h.
A once-daily dosing has been well validated for
thromboprophylaxis. Prophylactic regimens of the
different LWMHs currently available are men-
tioned in Table 4.
Since the appearance of the first guidelines in
2000, the attitude towards patients receiving pro-
phylactic doses of LMWHs has not changed. An
interval of at least 12 h between the last prophylac-
tic dose of LMWH and the subsequent neuraxial
blockade should be respected (Class IIa, level C).
When prophylaxis is initiated after the procedure,
the administration of LMWHs should be delayed
until 4 h after the neuraxial technique (Class IIa,
level C).
A neuraxial catheter should not be manipulat-
ed or removed earlier than 12 h after LMWH
administration (Class IIa, level C). The subsequent
dose of a LMWH should be delayed until at least 4
hours after the removal of manipulation of the neu-
raxial catheter (Class IIa, level C). LMWHs can
induce thrombocytopenia (i.e. heparin-induced
thrombocytopenia or HIT), although the incidence
is 10 times lower than for UH (33). A platelet count
in patients that are or have been on LMWHs for at
least 5 d is advised (Class I, level B) (34).
Therapeutic administration
Low molecular weight heparins are also used
in intermediate (i.e. halftherapeutic) and therapeutic
doses in a once or twice daily schedule (Table 4). A
neuraxial block should not be performed earlier
than 24 h after the last intermediate or therapeutic
dose of LMWH (Class IIa, level B). If LMWH
treatment is to be continued following the surgical
procedure, only prophylactic doses should be used
as long as a neuraxial catheter is in place. As dis-
cussed previously, a neuraxial catheter should not
be removed within 12 h after prophylactic LMWH
administration and a time window of at least 4 h
before the injection of the subsequent dose needs to
be respected (Class IIa, level C). For the first
administration of LMWH after neuraxial catheter
removal, a prophylactic dose is recommended but
therapeutic doses may be used thereafter (Class IIb,
level C). Because of the risk of HIT, a platelet count
is advised if LMWHs have been used for at least 5
d (Class I, level B) (34).
UNFRACTIONATED HEPARIN THERAPY
Therapeutic preoperative use
Unfractionated heparin produces an anticoag-
ulant effect via an anti-thrombin dependent inhibi-
tion of factor IIa and Xa.
An ongoing treatment with therapeutic doses
of UH is an absolute contraindication to the per-
formance of a neuraxial anesthetic technique (Class
III, level C). However, the cessation of an ongoing
UH therapy should always be discussed with the
treating physician(s). Before inserting an epidural
and/or spinal needle/catheter, the normalization of
coagulation parameters must be assessed by labora-
tory tests such as the activated partial thromboplas-
tin time (aPTT) or the activated clotting time
(ACT), which should be within normal limits
(Class IIa, level C) (Table 5). The ACT is a point-
of-care test (POCT) that can be used as an alterna-
tive to the aPTT. The normal values of both the
aPTT and ACT will vary from hospital to hospital
as they depend upon the specific assay used locally.
UH can induce HIT. A platelet count in patients that
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have been on UH for at least 5 d is advised (Class I,
level B) (34).
Therapeutic intraoperative use
The use of UH during surgery does not neces-
sarily preclude the use of a neuraxial anesthetic
technique. There is evidence that this can be safely
done provided the UH is administered no earlier
than at least 1 h after performing the neuraxial anes-
thetic technique (Class IIa, level C) (35, 36).
In case of a bloody puncture, it is recommend-
ed that a low-dose of UH (i.e. 5000 IU) be avoided
for 1-2 h and that full intraoperative heparinization
is delayed for 6-12 h, and if necessary, to postpone
surgery to the next day (Class IIa, level C).
The anesthetist should discuss with the sur-
geon whether to continue, stop, or temporarily
antagonize therapeutic heparin anticoagulation in
order to determine the optimal timing for catheter
removal.
At all times, catheters should only be removed
when the aPTT (Table 5) or the ACT are within nor-
mal range (Class IIa, level C) and at least 1 h before
any subsequent heparin administration. With the
current knowledge, the use of neuraxial techniques
remains at the least experimental when higher (i.e.
supratherapeutic) doses are used, as is the case in
cardiac surgery. Moreover, the use of neuraxial
blockade in cardiac surgery does not seem to have
any significant effects on morbidity and mortali-
ty (37-39), while there is a significant bleeding
risk (40). In sum, these findings may question the
use of neuraxial techniques in cardiac surgery
(Class IIb, level C).
SELECTIVE FACTOR XA INHIBITORS
Fondaparinux
Fondaparinux (Arixtra®) is a synthetic selec-
tive inhibitor of factor Xa. With a bioavailability of
almost 100 % and an elimination half-life of 18-
21 h, plasma levels will still be prophylactic after
24 h. Prophylactic fondaparinux is administered
subcutaneously once daily in a dose of 2.5 mg and
should be started 6-12 h postoperatively (41). The
half-life will be prolonged to 36-42 h if creatinine
clearance is 20-50 ml/min, when the dose should be
reduced to 1.5 mg (42). Fondaparinux should not be
used if creatinine clearance is inferior to 20 ml/min.
The preoperative administration of fondaparinux
may even increase the risk of intraoperative bleed-
ing without improving its thromboprophylactic effi-
cacy (43). The use of higher doses will increase
bleeding tendency and is only approved for thera-
peutic anticoagulation. Fondaparinux has been suc-
cessfully used in the treatment of HIT, and the
ACCP currently recommends fondaparinux in
patients with strongly suspected (or confirmed) HIT
as an alternative, non-heparin anticoagulant for
thromboprophylaxis (44).
As fondaparinux is started postoperatively,
there should be no problem with the preoperative
insertion of an epidural/spinal needle for a single-
shot anesthetic technique. In case of a bloody tap,
an alternative method of thromboprophylaxis
should be considered, as insufficient data are avail-
able to safely initiate the use of fondaparinux. The
long half-life of the drug and its kidney-dependent
mode of elimination carry the inherent risk of
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Table 4
Prophylactic, intermediate and therapeutic doses of low molecular weight heparins
* 10 mg = 1000 IU anti-Xa (anti-Xa activity).
Prophylactic doses - SC Intermediate doses - SC Therapeutic doses - SC
Clexane®
(enoxaparin)
1 × 0,5 mg*/kg/24 h 1 × 20-40 mg*/24 h
(1 × 0.5 mg*/kg/24 h)
2 × 1 mg*/kg/24 h 
or 1 × 1.5 mg*/kg/24 h
Fragmin®
(dalteparin)
1 × 2500-5000 IU anti-Xa/24 h 1 × 100 IU anti-Xa/kg/24 h 2 × 100-IU anti-Xa/kg/24 h 
or 1 × 200 IU anti-Xa/kg/24 h
Fraxiparine®
(nadroparin)
1 × 2850-5700 IU anti-Xa/24 h 1 × 90 IU anti-Xa/kg/24 u 2 × 90 IU anti-Xa/kg/24 h
Fraxodi®
(nadroparin)
/ / 1 × 171 aXa IU/kg/24 h
Innohep®
(tinzaparin)
1 × 50 IU anti-Xa/kg/24 h 1 × 90 IU anti-Xa/kg/24 h 1 × 175 IU anti-Xa/kg/24 h
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 accumulation, especially in the elderly. This should
be taken into account when considering the use of a
neuraxial catheter. Moreover, the ACCP currently
recommends against the use of continuous epidural
analgesia in the presence of fondaparinux (28).
Instead, an alternative method of thromboprophy-
laxis should be used (e.g. LMWH). If for some rea-
son patients with an indwelling epidural/spinal
catheter are treated with fondaparinux, the removal
of these catheters can be performed under the con-
ditions used in the EXPERT study (Evaluation of
arixtra for the prevention of venous thromboem-
bolism in daily practice) (45) : i.e., respecting an
interval of 36 h after the last dose of fondaparinux
and longer if creatinine clearance is below
50 ml/min, while the next dose of fondaparinux was
administered no earlier than 12 h after catheter
removal. This practice did not increase the risk of
venous thromboembolism, while no spinal epidural
hematoma occurred. Still, the statistical power of
this study is too low to make any firm recommen-
dations. 
If therapeutic doses of fondaparinux (5-10 mg
per day) are used, neuraxial anesthesia techniques
should not be performed (Class III, level C).
Rivaroxaban and apixaban
Rivaroxaban (Xarelto®) is a selective inhibitor
of factor Xa that is administered orally once daily.
It is currently approved for the prevention of deep
venous thrombosis after total arthroplasty of the
knee or the hip. Rivaroxaban is more efficacious
than enoxaparin in preventing post-operative
venous thromboembolism (46) and first results
from the Rocket-AF trial suggest that it may be as
effective as warfarin in the prevention of cardioem-
bolism in patients with atrial fibrillation (47).
Although initial reports did not show an increased
bleeding tendency, a recent document from the U.S.
Food and Drug Administration (FDA) warned
against the use of rivaroxaban in thromboprophy-
laxis because of an increased risk for non-major
clinical bleeding events when compared to enoxa-
parin (48). Prophylaxis with rivaroxaban is initiated
6-8 h after surgery and maximum plasma levels will
be reached after 2-4 h following the administration
of a dose of 10 mg. The drug is eliminated both via
the kidney (33%) and the liver and has an elimina-
tion half-life of 5-9 h that is therefore only minimal-
ly influenced by renal function. According to the
manufacturer, the half-life can be prolonged to 11-
13 h in the elderly, but a dose adjustment is not nec-
essary. Routine monitoring of the anticoagulant
effect is not deemed necessary by the manufacturer
although both the prothrombin time (PT) and the
International Normalized Ratio (INR) are pro-
longed in a dose-dependent manner by rivaroxaban.
However, neither the PT nor the INR should be
used to decide whether or not it is safe to perform a
neuraxial block, as these tests were only validated
for vitamin K antagonists (VKAs). In the near future,
anti-Xa assays validated for the specific agents will
become available. As with most new antithrom-
botics, rivaroxaban cannot be antagonized.
A minimum time interval of 22-26 h should be
respected before a neuraxial catheter is removed
(Class IIa, level C). The next dose of rivaroxaban
should only be given 6 h after catheter removal
(Class IIb, level C). The manufacturer suggests that
in case of a bloody puncture the next administration
of rivaroxaban should be postponed for 24 h (49).
The available experience on the use of neuraxial
blockade is very limited, as most patients only
received single-shot spinal anesthesia or, as neurax-
ial catheters were removed before treatment was
started. As a result, extreme caution is mandatory
when using rivaroxaban in the presence of neuraxi-
al blocks (Class IIb, level C).
Apixaban (Eliquis®) is another oral, reversible
and selective inhibitor of factor Xa that is related to
rivaroxaban and has recently received approval of
the European Medicines Agency (EMEA) for post-
operative thromboprophylaxis in patients under -
going a total arthroplasty of the knee or the hip. It
is even less dependent on the kidney for its
Table 5
Laboratory investigations and neuraxial techniques
* INR, international normalized ratio
** Normal values depend on assay used locally in each hospital.
Without problems After individual evaluation
Prothrombin Time (PT) > 50% (INR* ≤ 1.4) 40-50% (INR* 1.4-1.7)
Activated Partial Thromboplastin
Time (aPTT)
Upper limit of normal** Exceeding upper limit of normal by 1-
4 sec**
Platelets > 80,000/µl 50,000-80,000/µl
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 elimination as 75% will be cleared via the hepatic
and biliary route resulting in a half-life ranging
from 10-15 h (50), with an average of 12.7 h (51).
Independent of this longer half-life, it is adminis-
tered in a twice-daily dose of 2.5 mg. Compared
to a twice-daily dose of enoxaparin 30 mg in
orthopedic surgery, it has a similar efficacy but with
a lower bleeding risk when started 12-24 h post -
operatively (52). When compared to a single daily
dose of enoxaparin 40 mg after knee and hip arthro-
plasty, it was associated with lower rates of venous
thromboembolism, without increased bleeding (53,
54). As for rivaroxaban, an antidote and a specific
monitoring technique are not available yet, but spe-
cific anti-Xa assays are under development.
Applying the 2 half-lives rule to apixaban would
imply that at least 26-30 h should have elapsed
since the last dose of apixaban (2.5 mg) and the
subsequent withdrawal of a neuraxial catheter
(Class IIa, level C). This also means that 1 dose of
apixaban should be skipped. Following catheter
withdrawal, the next dose of apixaban can be given
6 h later (Class IIb, level C). Similarly to rivaroxa-
ban - and to all new antithrombotic drugs in gener-
al - the experience with neuraxial anesthetic tech-
niques, even more so when catheters are consid-
ered, is limited. Extreme caution is recommended
when using neuraxial blocks in the presence of
apixaban (Class IIb, level C).
In the near future, rivaroxaban and apixaban
amongst others may replace vitamin K antagonists
(VKAs) in the prevention of stroke in the presence
of atrial fibrillation and for the acute treatment and
secondary prevention of venous thromboembolism.
The doses used for these indications are higher than
the doses used in prevention of venous thromboem-
bolism (i.e. rivaroxaban 20 mg/day, apixaban 5 mg
bid). Thus, the time interval by which these drugs
should be interrupted preoperatively to allow for
safe surgery should be longer. Because of the large
pharmacokinetic variability (i.e. absorption, distri-
bution and elimination) and the influence of patient
sex, age, weight and genetic polymorphism) time
intervals need to be defined but a delay of 4-5 half
lives has been suggested to ensure that there is no or
only a minimal residual anticoagulant effect at the
time of surgery (55) (Class IIb, level C). In a num-
ber of patients, and similar to VKAs, the interrupt-
ed treatment may have to be bridged temporarily
with UH or LMWH. If a neuraxial block is consid-
ered in those patients, the recommendations con-
cerning UH or LMWH apply. In any case, an ongo-
ing treatment with these higher doses of oral direct
thrombin inhibitors is an absolute contraindication
to neuraxial anesthesia and the presence of an
indwelling neuraxial catheter (Class III, level C).
Neuraxial instrumentation would only be possible
in the absence of any remaining anticoagulant
effect of the factor Xa inhibitor used and should
preferably be documented prior to any neuraxial
instrumentation via an anti-Xa assay calibrated for
the specific agent (i.e. anti-Xa activity < 0.1 IU/ml)
(Class IIb, level C). Postoperatively, rivaroxaban
and apixaban should only be restarted at least 6 h
after withdrawal of the neuraxial catheter and tak-
ing into account the adequacy of surgical hemosta-
sis (Class IIb, level C).
DIRECT THROMBIN INHIBITORS
Lepirudin
Hirudins are potent anticoagulants with an
essentially irreversible bivalent binding to both free
and bound thrombin via the active site of thrombin
and the fibrinogen-binding site. Although original-
ly prepared as unrefined extracts from leeches,
modern hirudins are either recombinants such as
lepirudin and desirudin, or analogues like
bivalirudin. Desirudin is not available in Belgium
while bivalirudin is only (to be) used in patients
undergoing a percutaneous coronary intervention
although it has also been used to replace UH in car-
diac surgery patients with (a recent history of) a
type II HIT. Therefore, the latter 2 drugs will not be
discussed any further as this is beyond the scope of
this chapter.
Lepirudin on the other hand is mainly used in
the prevention and treatment of venous thromboem-
bolism in patients with type II HIT. The drug has a
half-life of 1.3-3 h, which substantially increases
with decreasing renal function. Prophylactic doses
range from 10-15 mg twice daily administered sub-
cutaneously. The therapeutic use of lepirudin is
started at a dose of 0.1 mg kg-1 h-1 in the presence of
normal renal function and the effect is monitored
using the aPTT or the ecarin clotting time
(ECT) (56). Finally, hirudins are potentially
immunogenic with antibodies developing in 40% of
patients. This immunogenicity increases with the
duration of the treatment and may prolong the anti-
coagulant effect (57). Hirudins cannot be antago-
nized (58).
Once again, there are almost no data on the use
of major neuraxial blocking techniques in patients
treated with lepirudin, while a case of an epidural
hematoma in a patient treated with lepirudin has
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been reported (59). Based on the pharmacokinetic
data, it is recommended that epidural and/or spinal
needle/catheter insertion or catheter manipulation/
removal should only be performed at least 8-10 h
after the last dose and 2-4 h prior to the next admin-
istration (Class IIa, level C). These time intervals
only apply to patients with normal renal function
and in the absence of antibody formation. A remain-
ing anticoagulant effect should always be excluded
through the use of the aPTT or the ECT before any
neuraxial manipulation (Class IIa, level C).
Dabigatran
Dabigatran (Pradaxa®) is a novel monovalent
direct thrombin inhibitor. The prodrug dabigatran
etexilate is ingested orally and converted by plasma
esterases into the active dabigatran. The drug is
approved for the prophylaxis of venous throm-
boembolism following elective total hip or knee
replacement. Studies indicated that the drug has a
prophylactic efficacy and bleeding tendency com-
parable to that of enoxaparin (60). Dabigatran has a
long half-life of 12-17 h and is eliminated mainly
via the kidney. An antidote is not available but a
number of nonspecific measures such as hemodia-
lyisis or the administration of prothrombin complex
concentrate (PCC), Factor eight inhibitor bypassing
activity (FEIBA) or recombinant factor VIIa have
been used with mixed results (61). The maximum
plasma concentration will be reached after 2-4 h.
For the prevention of venous thromboembolism
after orthopedic surgery, dabigatran is initiated with
a dose of 75 mg (creatinine clearance 30-50 ml min-
1) or 110 mg (normal kidney function) 1 to 4 h after
surgery has been completed. From day 1 postoper-
atively, the standard dose of once daily 150 mg or
220 mg respectively is administered and repeated
every 24 h thereafter. The anticoagulant effect can
be quantified using the thrombin clotting time (TT),
the ECT or the TT determined by Hemoclot throm-
bin inhibitor assay (61).
As prophylaxis with dabigatran is started post-
operatively, there should be no problem with single-
shot neuraxial anesthesia. The experience with
dabigatran and indwelling neuraxial catheters is
minimal, if not non-existent : the epidural catheters
that were used in the studies with dabigatran were
all withdrawn at least 4 h before treatment with
dabigatran was started. The 12-17 h half-life (in the
presence of normal renal function) suggests that a
time interval of at least 34 h should be respected
between the last dose of dabigatran and catheter
manipulation or withdrawal, while the next dose of
dabigatran should only be given at least 6 h later.
However, the manufacturer recommends that dabi-
gatran should not be used in patients undergoing
anesthesia with postoperative indwelling epidural
catheters (62) (Class III, level C). This warning
may have important medicolegal consequences if a
spinal bleeding would develop following the use of
an indwelling neuraxial catheter in a patient treated
with dabigatran.
Recently, the Committee for Medicinal
Products for Human Use of the EMEA adopted a
positive opinion on a new indication for dabigatran
in the prevention of stroke and systemic embolism
in adult patients with nonvalvular atrial fibrillation.
Similar to the oral factor Xa inhibitors, the doses
used for these indications are higher than the doses
used in prevention of venous thromboembolism
(i.e. 220-300 vs. 150-220 mg/day). This also
implies that a treatment with dabigatran should be
interrupted preoperatively for a longer time to allow
for safe surgery. These time intervals still need to be
defined but, similar to the oral factor Xa inhibitors,
a delay of 4-5 half-lives has been suggested to
ensure no or only a minimal residual anticoagulant
effect at the time of surgery (55) (Class IIb, level
C). As is current practice in patients treated with
VKAs, the interrupted treatment may have to be
bridged temporarily with UH or LMWH. If a
 neuraxial block is considered in those patients, the
recommendations concerning UH or LMWH apply.
In any case, an ongoing treatment with higher doses
of dabigatran represents an absolute contraindica-
tion to neuraxial anesthesia and the presence of an
indwelling neuraxial catheter (Class III, level C).
Neuraxial instrumentation is only possible in the
absence of any remaining anticoagulant effect of
dabigatran and should always be documented prior
to any neuraxial instrumentation via the use of the
TT or ECT (Class IIb, level C). Postoperatively,
dabigatran should only be restarted at least 6 h after
withdrawal of the neuraxial catheter and taking into
account the surgical bleeding risk (Class IIb, level
C).
VITAMIN K ANTAGONISTS
Vitamin K antagonists (VKAs), such as aceno-
coumarol (Sintrom®), phenprocoumon (Marcou -
mar®) and warfarin (Marevan®), cause the produc-
tion of dysfunctional coagulation factors II, VII, IX
and X, which are no longer capable of chelating
calcium , essential for their binding to phospholipid
membranes during coagulation.
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An uninterrupted chronic and effective thera-
py with VKAs is an absolute contraindication to
neuraxial anesthesia (Class III, level C). When
regional anesthesia is deemed necessary, VKA ther-
apy has to be stopped with a delay depending on the
half-life of the oral anticoagulant used, the initial
INR or PT, and the patient’s general condition. In
most cases, this treatment will be interrupted peri-
operatively and temporarily bridged with UH or
LMWH (63). Under these circumstances, the spe-
cific recommendations for that type of therapy
should be applied. With respect to the timing of
neuraxial anesthesia and catheter removal, the PT
should be above 50% (INR equal to or below 1.4).
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Non-steroidal anti-inflammatory drugs
(NSAIDs) cause a reversible inactivation of both
cyclo-oxygenase I and II, thereby causing platelet
aggregation inhibition. The half-life of the NSAIDs
used determines the duration of this effect. In con-
trast, the specific cyclo-oxygenase II inhibitors (i.e.
coxibs) do not possess any significant platelet
aggregation inhibiting effect (64).
If an NSAID is used as the sole agent interfer-
ing with normal coagulation, there are no data
available to suggest that there is an increased risk of
spinal hematoma formation in patients receiving
neuraxial blockade (Class IIb, level C).
Also, there are no data in the literature sug-
gesting that a combination of NSAIDs increases the
risk of a spinal hematoma.
ANTIPLATELET THERAPY
Dipyridamole
No specific precautions have to be considered
if dipyridamole is used as the sole antithrombotic
agent (Class IIb, level C).
Low-dose acetylsalicylic acid (i.e. aspirin®)
Acetylsalicylic acid (ASA) produces an irre-
versible inactivation of cyclo-oxygenase. Low-dose
ASA (60-300 mg) mainly inhibits thromboxane A2
(a potent vasoconstrictor and platelet aggregation
stimulator) and not so much prostacyclin (a potent
vasodilator and platelet aggregation inhibitor).
Overall, low-dose ASA will result in platelet aggre-
gation inhibition that will exceed the last adminis-
tration of the drug by an entire platelet lifetime (i.e.
7-10 d).
There are no data suggesting that low-dose
ASA in isolation is associated with an increased
risk of spinal hematoma in the presence of a normal
platelet count (Class IIb, level C).
The latter was also true for the combination of
low-dose ASA with dipyridamole. However, a
study looking at the use of the combination of
25 mg of aspirin plus 200 mg of extended-release
dipyridamole twice daily vs. clopidogrel 75 mg
once daily for recurrent stroke found a 15%
increase in major hemorrhagic events in the patients
treated with the ASA-dipyridamole combination
(65). In view of these results, it may be wiser to
withhold the ASA-dipyridamole combination for 24
h prior to any neuraxial instrumentation (Class IIb,
level C). This will allow the additional dipyri-
damole effect to wear off while the ASA will still
remain largely effective.
Ticlopidine / Clopidogrel
The thienopyridines ticlopidine and clopido-
grel are prodrugs that are activated by the liver to
active metabolites that inhibit adenosine diphos-
phate (ADP)-induced platelet aggregation through
an interaction with the platelets P2Y12 receptor and
by interfering with platelet-fibrinogen binding.
Because of this hepatic conversion, it will take sev-
eral days before a full antiplatelet effect is reached,
although this process is dose dependent (i.e. the
higher the loading dose, the faster the onset). The
antiplatelet effect is irreversible and cannot be
antagonized. Ticlopidine has an elimination half-
life of 30-50 h after a single oral dose but up to 96 h
after repeated dosing. Clopidogrel has an elimina-
tion half-life of 120 h. Because of the irreversible
defect in a platelet protein, the platelet inhibition
will persist for 7 and 10 d after clopidogrel and
ticlopidine cessation, respectively.
Neuraxial anesthesia should be used only if
ticlopidine or clopidogrel are no longer active : i.e.
administration was stopped for at least 7 d for clopi-
dogrel, and for 10 d for ticlopidine (Class IIa,
level C). The next dose of ticlopidine or clopidogrel
can be administered after catheter removal. If
thienopyridines are used because of the recent
implantation of a coronary stent, they should not be
stopped only because of the performance of a neu-
raxial block (Class III, level C). In that case, an
interdisciplinary approach including the surgeon,
the cardiologist and the anesthetist is mandatory.
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Prasugrel
Prasugrel (Efient®) is a new oral third-genera-
tion thienopyridine that also produces an irre-
versible inhibition of platelet aggregation via the
platelet P2Y12 receptor, which cannot be antago-
nized. Prasugrel is also an inactive prodrug that is
metabolized by the liver into an active metabolite.
Compared to clopidogrel, this conversion occurs
much faster and more efficiently, and results in a
significantly more active compound (66). Thirty to
60 min after oral ingestion, maximum plasma levels
will be reached. Elimination of the drug occurs
mainly via the kidneys with an elimination half-life
of about 7.4 h, but following cessation of treatment,
the antiplatelet effect will last 7-10 d (67).
It is indicated for the prevention of
atherothrombotic events in patients with acute coro-
nary syndrome undergoing primary or delayed per-
cutaneous coronary intervention. It is more efficient
than clopidogrel in the prevention of cardiovascular
death, non-fatal myocardial infarction and non-fatal
stroke (68, 69). However, the use of prasugrel may
be associated with a higher bleeding tendency. As a
result, the manufacturer advises that prasugrel be
stopped at least 7 d before elective surgery (70).
Considering the higher efficacy and bleeding risk of
prasugrel compared to clopidogrel, neuraxial anes-
thesia should not be performed unless a time inter-
val of 10 d has elapsed since the last dose of prasug-
rel (Class III, level C). The next dose should be
administered 6 h after catheter removal (Class IIb,
level C).
Ticagrelor
Ticagrelor (Brilique®) is a pyrimidine and dif-
fers from thienopyridines by reversibly binding to
the platelet P2Y12 receptor and noncompetitively
blocking ADP-induced platelet activation (71, 72).
Unlike the thienopyridines, ticagrelor does not
require metabolic activation. As a result, it has a
faster onset of action and less interpatient variabili-
ty. Ticagrelor has a relatively short half-life of 7-8 h
and has to be administered twice daily via the oral
route (72-74). Following treatment cessation,
platelet function recovers after 4.5 d (75).
The PLATO trial compared the effect of clopi-
dogrel and ticagrelor in patients having an acute
coronary syndrome with or without ST segment
elevation and demonstrated a significant reduction
of risk of death from vascular cause, myocardial
infarction or stroke in the ticagrelor group (76-78).
The occurrence of major bleeding was similar in
both groups, while non-procedure-related bleeding
occurred more frequently in the ticagrelor
group (75, 77). Ticagrelor was approved in
December 2010 for use in the prevention of
atherothrombotic events in adult patients with acute
coronary syndromes, including patients managed
medically and those managed with revasculariza-
tion. To date, no data are available regarding the
perioperative use of ticagrelor. However, the manu-
facturer recommends that ticagrelor should be dis-
continued 7 days prior to surgery (79). Therefore,
neuraxial anesthesia should only be performed at
least 7 d after treatment interruption (Class III,
level C). The next dose of ticagrelor should only be
administered 6 h after catheter withdrawal (Class
IIb, level C).
Glycoprotein IIb/IIIa receptor antagonists
Abciximab (Reopro®), eptifibatide
(Integrilin®) and tirofiban (Aggrastat®) represent
the strongest form of platelet aggregation inhibiting
therapy currently available. By inhibiting the
IIb/IIIa receptor, they prevent the binding of
platelets to fibrinogen and von Willebrand factor
and thus platelet aggregation. Platelet function test-
ing can be used to assess the pharmacodynamic
effects of IIb/IIIa receptor antagonists (it is probably
a far more effective, but slower, way of assessing
platelet aggregation inhibition) (80, 81). The anti -
platelet effects are reversible and will disappear
spontaneously about 8 h and 24-48 h after discontin-
uing eptifibatide/tirofiban and abciximab adminis-
tration, respectively. All glycoprotein IIb/IIIa recep-
tor antagonists, but especially abciximab, can cause
a profound thrombocytopenia, which may appear
within 1-24 h after the first administration (82-84). 
These drugs are only used in acute coronary
syndromes for emergency catheterisation, and are
often combined with UH and ASA in this setting. In
a number of these cases, cardiac surgery will be
performed and there will always be a need for pro-
longed anticoagulation. Therefore, major neuraxial
anesthetic techniques should not be used in patients
treated with glycoprotein IIb/IIIa receptor antago-
nists (Class III, level C). If a neuraxial catheter has
to be withdrawn after their administration, it should
not be performed less than 8-10 h or 48 h after the
last dose of eptifibatide/tirofiban or abciximab,
respectively and 2-4 h prior to the next administra-
tion of these drugs. Also, a platelet count should
always be obtained prior to any instrumentation of
the patient so as to exclude any thrombo cytopenia.
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Selective serotonin reuptake inhibitors (SSRIs)
A dysfunction of serotonergic neurotransmis-
sion has consistently been found in states of major
depression and selective serotonin inhibitors are
now often included in its treatment. Serotonin is
also involved in platelet aggregation. Selective
serotonin reuptake inhibitors (SSRIs) will block the
reuptake of serotonin from the plasma by the
platelets causing depletion of serotonin in platelets
and produce the downregulation of serotonin recep-
tors both in neurons and platelets (85). Overall, the
antiplatelet effects of SSRIs cover a whole spec-
trum of decreased platelet-binding affinity, block-
ade of platelet calcium mobilization and reduced
platelet secretion (86-88). Whether the periopera-
tive administration of SSRIs may cause significant
bleeding still remains somewhat controversial, but
since the beginning of the 1990s an increasing num-
ber of case reports can be found in the litera-
ture (89-93). A recent review of the literature found
that the risk of upper gastrointestinal bleeding was
doubled in patients taking SSRIs when compared to
patients taking other antidepressants (94). Also,
preoperative SSRI use increased perioperative
blood transfusion requirements in orthopedic
patients (95) and the need for surgical reoperation
because of bleeding after breast surgery (96). In
contrast, the preoperative use of SSRIs in patients
undergoing coronary artery bypass grafting did not
seem to increase the perioperative bleeding
risk (97-99). Interestingly, the SSRIs most associat-
ed with bleeding are those with the most profound
serotonin reuptake inhibition : fluoxetine, sertraline
and paroxetine (100). Finally, the SSRI-associated
increase in bleeding tendency is mostly seen in
patients that were concomitantly treated with
antithrombotic drugs such as ASA, thienopyridines,
NSAIDs, VKAs and LMWHs (101-105).
Despite their extensive use, there have been no
reports of a spinal hematoma following a neuraxial
block in the presence of SSRIs. Considering the
data that are currently available, the preoperative
use of SSRIs does not represent a contraindication
to a neuraxial block and no recommendations con-
cerning the preoperative withdrawal of these drugs
can be made (Class IIb, level C).
FIBRINOLYTIC THERAPY
Thrombolytic/fibrinolytic drugs currently
available include alteplase (Actilyse®),
tenecteplase (Metalyse®), reteplase (Rapilysin®)
and urokinase (Actosolv®). These drugs dissolve
already formed clots through the activation of the
endogenous  proteolytic plasmin system. Although
the half-lives of thrombolytic/fibrinolytic drugs are
relatively short-lasting, their fibrinolytic effects
may persist for several days.
Therapy with these agents is an absolute con-
traindication to neuraxial blockade (Class III,
level C). When surgeons or other practitioners
insist on the use of these agents when neuraxial
techniques have recently been performed, all par-
ties should document this in the patient’s records. If
a neuraxial catheter was already in situ when these
drugs were administered – very often in an emer-
gency situation such as a life-threatening pulmonary
embolism or a myocardial infarction – it is safer to
leave the catheter in place until all thrombolytic
effects have disappeared. This can be documented
by laboratory values, including fibrinogen levels
(and perhaps thromboelastography). If any other
antithrombotics, such as UH, are used concomitant-
ly then the recommendations for these drugs do
apply.
HERBAL MEDICINE
A significant number of surgical patients
chronically use herbal medications such as aloe,
echinacea, dwarf palm, ephedra, ginger, garlic, gin-
seng or ginkgo-biloba. The latter three have been
linked to an increased bleeding tendency because of
an interaction with platelets and VKAs. Still, there
is only one report of a spontaneous epidural
hematoma associated with the use of garlic (106).
In addition, in vivo platelet function was not affect-
ed by the administration of garlic, ginkgo or gin-
seng (107, 108). In summary, there are insufficient
data available to decide whether to systematically
stop these medications preoperatively or to cancel
surgery in patients still treated with these com-
pounds as herbal preparations, by themselves, do
not appear to represent an additional significant
risk for the development of spinal hematoma in
patients having neuraxial anesthesia (10, 109).
However, the simultaneous use of these medica-
tions with other drugs affecting coagulation such as
oral anticoagulants may increase bleeding tendency
(Class IIa, level C).
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